课题基金 / 基金详情

CONCOMITANT INFECTIONS WITH HIV AND HTLV-I/HTLV-II

CONCOMITANT INFECTIONS WITH HIV AND HTLV-I/HTLV-II
HIV 和 HTLV-I/HTLV-II 合并感染
批准号:
3195627
负责人:
WILLIAM W HALL
金额:
$23.1万
依托单位国家:
美国
项目类别:
财政年份:
1990
资助国家:
美国
项目状态:
已结题
起止时间:
1990-07-01 至 1993-10-30

项目摘要

项目成果

WILLIAM W HALL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Previous serological studies have shown that certain patients infected with Human Immunodeficiency Virus (HIV) may also be infected with the Human T-cell lymphotropic Virus type I (HTLV-1) and /or type II (HTLV-II). In preliminary studies using sera from 629 HIV infected patients we could show that although sexual transmission of HIV-I/HTLV-II certainly occurs intravenous drug abusers (IVDAs) had a much higher seroprevalence of infection than any other AIDS risk group. It could also be shown that Black and Hispanic IVDAs had significantly higher seropositivity rates than whites and that seropositivity increased with age. Unfortunately serological methods cannot distinguish between infection by the two viruses because of their antigenic cross-reactivity. This requires virus isolation with molecular analysis and /or PCR amplification studies. Using a novel co-cultivation method we have successfully isolated HTLV-II from five IVDAs and provirus mapping of the isolates have suggested that there may be some genetic heterogeneity in this family of viruses. PCR amplificaticn methods have been developed which are specific and sensitive for provirus detection in peripheral blood mononuclear cells and using this method we were able to detect HTLV-II infection in an additional eleven IVDAs. We wish to expand on these preliminary findings and propose the following studies. First we will extend our serological studies to a larger study group to allow the identification of a larger number of dually infected patients. This will be followed by PCR amplification studies to specifically identify the HTLV involved. Virus isolation with provirus mapping will be continued to investigate how significant genetic heterogeneity is in the HTLV-II family. Finally we plan a prospective study of the clinical and immunological features of dually infected IVDAs which with specific virus identification may allow a better understanding of their role in human disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
STUDY OF HUMAN T-CELL LEUKEMIA VIRUS TYPE I AND TYPE 11
  • 批准号:
    6307541
  • 项目类别:
  • 资助金额:
    $0.82万
  • 财政年份:
    1999
  • 负责人:
    WILLIAM W HALL
  • 依托单位:
STUDY OF HUMAN T-CELL LEUKEMIA VIRUS TYPE I AND TYPE 11
  • 批准号:
    6279526
  • 项目类别:
  • 资助金额:
    $0.42万
  • 财政年份:
    1997
  • 负责人:
    WILLIAM W HALL
  • 依托单位:
MOLECULAR AND IMMUNOLOGIC STUDIES OF HUMAN T CELL LEUKEMIA VIRUS TYPE II
  • 批准号:
    6246936
  • 项目类别:
  • 资助金额:
    $5.86万
  • 财政年份:
    1997
  • 负责人:
    WILLIAM W HALL
  • 依托单位:
HUMAN T CELL LEUKEMIA VIRUS TYPE I & TYPE II
  • 批准号:
    6249509
  • 项目类别:
  • 资助金额:
    $1.24万
  • 财政年份:
    1996
  • 负责人:
    WILLIAM W HALL
  • 依托单位:
国内基金
海外基金
自供能传感阵列同步量化游离DNA与PSA实现前列腺癌的诊断和预后判断
  • 批准号:
    JCZRLH202601177
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
二氢杨梅素通过线粒体代谢重编程抑制DNA同源重组修复逆转口腔癌细胞放疗抵抗的机制研究
  • 批准号:
    2026JJ80500
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    阳帆
  • 依托单位:
乳酸通过ESM1-Akt-MDM2-p53通路调控卵巢癌DNA损伤和抗肿瘤免疫应答的分子机制研究
  • 批准号:
    2026JJ81975
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    肖娇
  • 依托单位:
淫羊藿苷通过TET2介导DNA去甲基化调控Hippo-YAP/TAZ通路逆转绝经后骨质疏松症成血管-成骨耦联失衡的机制研究